Sanuwave Health (SNWV) Stock Price, News & Analysis

Company Overview

Sanuwave Health, Inc. is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S. Food and Drug Administration for treatment of chronic diabetic foot ulcers. This portable, hand-held device provides a convenient alternative to conventional wound-care methods by delivering precision acoustic pulses directly to the affected tissue, thereby promoting neovascularization and reducing healing times. Sanuwave also supplies disposable treatment cartridges and related consumables to healthcare providers, and has established distribution agreements in North America and select overseas markets to broaden patient access.

Headquartered in Alpharetta, Georgia, Sanuwave Health originated as Tissue Regeneration Systems, Inc. before adopting its current name to reflect an expanded focus on regenerative medicine technologies. Under the leadership of Chief Executive Officer Jeff Bean, the company continues to advance its clinical research programs, pursue regulatory clearances for additional indications, and explore strategic partnerships. Sanuwave’s ongoing mission is to deliver innovative, non-invasive therapeutic solutions that improve patient outcomes and reduce healthcare costs worldwide.

Key Stats

• Today's Range: $35.87 to $37.50
• 50-Day Range: $33.17 to $45.00
• 52-Week Range: $5.63 to $46.58
• Volume: 29,349 shs
• Average Volume: 39,591 shs
• Market Capitalization: $316.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

Sanuwave Health Stock Analysis - MarketRank™

Sanuwave Health scored higher than 66% of companies evaluated by MarketBeat, and ranked 738th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Sanuwave Health has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Sanuwave Health has a consensus price target of $55.00, representing about 48.7% upside from its current price of $36.98.

Amount of Analyst Coverage

Sanuwave Health has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.95% of the float of Sanuwave Health has been sold short.

Short Interest Ratio / Days to Cover

Sanuwave Health has a short interest ratio ("days to cover") of 6.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanuwave Health does not currently pay a dividend.

Dividend Growth

Sanuwave Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.95% of the float of Sanuwave Health has been sold short.

Short Interest Ratio / Days to Cover

Sanuwave Health has a short interest ratio ("days to cover") of 6.

Change versus previous month

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.58

News Sentiment

Sanuwave Health has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Sanuwave Health this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanuwave Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.90% of the stock of Sanuwave Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.53% of the stock of Sanuwave Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SNWV Stock Analysis - Frequently Asked Questions

How have SNWV shares performed this year?

Sanuwave Health's stock was trading at $37.61 at the beginning of the year. Since then, SNWV shares have decreased by 1.7% and is now trading at $36.98.

How were Sanuwave Health's earnings last quarter?

Sanuwave Health Inc. (NASDAQ:SNWV) issued its quarterly earnings data on Friday, August, 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The firm had revenue of $10.16 million for the quarter, compared to the consensus estimate of $10.14 million.
Read the conference call transcript.

Who are Sanuwave Health's major shareholders?

Sanuwave Health's top institutional shareholders include Opaleye Management Inc. (11.44%), AWM Investment Company Inc. (5.71%), Geode Capital Management LLC (1.84%) and Stonebridge Wealth Management LLC (0.60%). Insiders that own company stock include Peter Stegagno and Iulian Cioanta.
View institutional ownership trends.

How do I buy shares of Sanuwave Health?

Shares of SNWV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SNWV
• Previous Symbol: NASDAQ:SNWV
• CIK: 1417663
• Web: N/A
• Phone: (770) 419-7525
• Fax: 770-419-8634
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Sanuwave Health: $55.00
• High Price Target: $55.00
• Low Price Target: $55.00
• Potential Upside/Downside: +49.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$31.37 million
• Net Margins: -97.03%
• Pretax Margin: -96.96%
• Return on Equity: N/A
• Return on Assets: -135.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $32.63 million
• Price / Sales: 9.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.49) per share
• Price / Book: -24.69

Miscellaneous

• Outstanding Shares: 8,570,000
• Free Float: 7,291,000
• Market Cap: $315.29 million
• Optionable: N/A
• Beta: 1.39